After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with a ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

Building Resilience in Education Systems presents 13 chapters on strengthening education system resilience, written specifically for policy makers and practitioners. The book examines diverse contexts ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

NCBiotech's Ambassador Community Event will be held at Biogen's Community Lab on February 20. Learn about recent opportunities and updates in NC life sciences, share your outreach strategies and ...

Donald Trump is considering to sell two iconic Francisco skyscrapers in a bid to save money by skipping building maintenance, according to a new report. President Donald Trump is considering to ...